Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0HMXA | ISIN: FR0010095596 | Ticker-Symbol: C4X
Frankfurt
21.11.24
09:06 Uhr
0,063 Euro
-0,009
-12,34 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
VALERIO THERAPEUTICS Chart 1 Jahr
5-Tage-Chart
VALERIO THERAPEUTICS 5-Tage-Chart
RealtimeGeldBriefZeit
0,0730,07617:26

Aktuelle News zur VALERIO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrMeeting of the Board of Directors of Valerio Therapeutics S.A. on November 13, 2024115Regulatory News: At its meeting of November 13, 2024, the Board of Directors of Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), ("Valerio Therapeutics" or the "Company") decided to appoint...
► Artikel lesen
VALERIO THERAPEUTICS Aktie jetzt für 0€ handeln
11.10.Valerio Therapeutics Société anonyme reports 1H results2
30.09.Valerio Therapeutics S.A.: Valerio Therapeutics Reports its Half-Year 2024 Financial Results and Provides an Update on its Activities295Acquisition of Emglev Therapeutics to focus on discovering single-domain antibodies (sdAbs) The VIO-01 trial is currently in Phase 1 dose escalation R&D efforts maintained for optimization...
► Artikel lesen
30.09.Valerio Therapeutics Acquires Emglev Therapeutics3
30.09.Valerio Therapeutics announces acquisition of Emglev Therapeutics3
30.09.Valerio Therapeutics S.A.: Valerio Therapeutics Acquires Emglev Therapeutics, a Single-Domain Antibody-Based Therapeutics Company282Valerio Therapeutics acquires Emglev Therapeutics, a single-domain antibody-based therapeutics company The transaction was completed on September 29, 2024, enabling the acquisition of Emglev's...
► Artikel lesen
05.08.Half-Year Liquidity Contract Statement for Valerio Therapeutics269Regulatory News: Under the liquidity contract entered into between VALERIO THERAPEUTICS (Paris:ALVIO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30...
► Artikel lesen
05.06.Valerio Therapeutics: Report on the Combined General Meeting of June 4, 2024474Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage...
► Artikel lesen
22.05.Valerio Therapeutics S.A.: Valerio Therapeutics Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial309The first dose level, evaluating 3 patients of the VIO-01-101 trial has been cleared as per the recommendations of the Clinical Review Committee. No clinically significant adverse events...
► Artikel lesen
30.04.Valerio Therapeutics S.A.: Valerio Therapeutics Reports Full Year 2023 Financial Results and Provides Clinical Development Updates729Cash position of €6.8 million as of December 31, 2023 Financial visibility until the end of fourth quarter of 2024 Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris:...
► Artikel lesen
06.02.Valerio Therapeutics S.A.: Valerio Therapeutics Announces a Capital Reduction Motivated by Losses by Reducing the Nominal Value of the Company's Shares469Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter "Valerio Therapeutics" or the "Company", a clinical-stage biotechnology company specializing in the development...
► Artikel lesen
31.01.Half-Year Liquidity Contract Statement for Valerio Therapeutics368Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) Under the liquidity contract entered into between Valerio Therapeutics and Kepler Cheuvreux, the following resources...
► Artikel lesen
12 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1